Brief: Bayer - European Medicines Agency Confirms Asundexian Marketing Authorization Application For Assessment In Secondary Prevention Of Ischemic Stroke
10/06/2026 07:32
BRIEF-Bayer - European Medicines Agency Confirms Asundexian Marketing Authorization Application For Assessment In Secondary Prevention Of Ischemic Stroke June 10 (Reuters) - BAYER AG BAYGn.DE:
EUROPEAN MEDICINES AGENCY CONFIRMS ASUNDEXIAN MARKETING AUTHORIZATION APPLICATION FOR ASSESSMENT IN SECONDARY PREVENTION OF ISCHEMIC STROKE
VALIDATION OF THE APPLICATION CONFIRMS THE SUBMISSION IS COMPLETE AND BEGINS THE EMA’S CENTRALIZED REVIEW PROCEDURE
Further company coverage: [BAYGn.DE]
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Bayer AG
See all newsBayer takes a giant leap toward investability
Europe Research Roundup: Barratt Redrow, Ferrari, KPN
Explainer: What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits?
Bayer shares soar over 18% after U.S. Supreme Court curbs Roundup lawsuits
US Supreme Court scales back Roundup cancer suits in win for Bayer (updated)